The May 29, 2026 PDUFA targets pediatric approval of Afrezza for type 1 or type 2 diabetes, leveraging INHALE-1 outcomes versus rapid-acting analogs plus basal insulin. INHALE-1 was open-label and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results